Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC) Meeting Abstract
| Authors: | Yoo, C.; Kim, K. P.; Kim, I.; Kang, M. J.; Cheon, J.; Kang, B. W.; Ryu, H.; Jeong, J.; Lee, J. S.; Kim, K. W.; Ryoo, B. Y.; Abou-Alfa, G. K. |
| Abstract Title: | Final results from the NIFTY trial, a phase IIb, randomized, open-label study of liposomal Irinotecan (nal-IRI) plus fluorouracil (5-FU)/leucovorin (LV) in patients (pts) with previously treated metastatic biliary tract cancer (BTC) |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S565 |
| Language: | English |
| ACCESSION: | WOS:000866211600055 |
| DOI: | 10.1016/j.annonc.2022.07.083 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 55P -- Source: Wos |
